| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 interim results example | Phase 3 | — | Subscribe to access the data. | Enzyme Replacement Therapies (ERT) | Dermatologic System | ||
Phase 3 interim results example | Phase 3 | — | Subscribe to access the data. | Enzyme Replacement Therapies (ERT) | Dermatologic System | ||
Phase 3 interim results example | Phase 3 | — | Subscribe to access the data. | Enzyme Replacement Therapies (ERT) | Dermatologic System |
Recent Updates
Recently added Catalysts
MediWound Ltd.$14.45
+0.22 (+1.55%)
D 34Pipeline Score Overvalued Pharma · Commercial
Market Cap
212.98 M
EPS
-2.10
P/E Ratio
-
Value Trade
2.26 M
-0.06 %
Week
-0.72 %
1 Month
-4.16 %
3 Month
-3.38 %
6 Month
-35.09 %
5 Year
-85.19 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
52.11 K
52 Week Range
14.90 - 22.51
% held by Insiders
25.52 %
% held by Institutions
53.11 %
Enterprise Value
168.62 M
Total Shares
12.85 M
Short %
16.8 %
Float Shares
9.62 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for MediWound Ltd.
687Total events
4Upcoming
201Tier-1 (high impact)
2013 – 2028Coverage
Upcoming catalysts 2
TBD
T2Trial Initiation
Subscribe to view catalyst details
TBD
T3Enrollment Update
Subscribe to view catalyst details
Event history 2
TBD
◆Trial InitiationEscharExApprovedTrial
Subscribe to view catalyst details
TBD
◆Quarterly UpdateCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-08-13 | EscharEx® (bromelain-based, bioactive enzymatic therapy) | phase 2 data readout | Phase 2 | — | – | – | – |
2025-08-13 | EscharEx® (bromelain-based, bioactive enzymatic therapy) | phase 2 data readout | Phase 2 | — | – | – | – |
2025-08-13 | EscharEx® (bromelain-based, bioactive enzymatic therapy) | phase 2 data readout | Phase 2 | — | – | – | – |
Drug Pipeline Intelligence
D34
Pipeline Score $52M
Pipeline ValueOvervalued
Valuation Signal4
Drugs Scored0.2x
rNPV / MCap Top 47%
Micro Cap (rank 485 of 913)
Percentile RankMediWound Ltd. faces pipeline headwinds (34/100), with $500M risk-adjusted pipeline value, led by EscharEx in Hard to Heal Wounds (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EscharEx Small molecule | Venous Leg Ulcer (VLU) | Phase 3 | NCT06568627 | 50% | $414M | RECRUITING | 216 | STALLED | B (67) | Mar 1, 2027 | LOW_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
EscharEx | venous leg ulcers | Phase 3 | 2026-04-07 | superior debridement with EscharEx versus SANTYL across multiple non-viable tissue components Read More | MediWound to Present New EscharEx Data at Leading Wound Care Conferences Read More | |
EscharEx | venous leg ulcers | Phase 3 | 2026-04-07 | superior debridement with EscharEx versus SANTYL across multiple non-viable tissue components Read More | MediWound to Present New EscharEx Data at Leading Wound Care Conferences Read More | |
EscharEx | venous leg ulcers | Phase 3 | 2026-04-07 | superior debridement with EscharEx versus SANTYL across multiple non-viable tissue components Read More | MediWound to Present New EscharEx Data at Leading Wound Care Conferences Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MDWD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MDWD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MDWD▼ -14.1%on this news
MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
MediWound Ltd. reported its first quarter 2026 financial results, highlighting ongoing progress in the Phase III VALUE trial for EscharEx and reaffirming its revenue guidance of $24-26 million for the year. Despite a revenue decline to $1.5 million, the company noted strong engagement from collaborators and expanding adoption of NexoBrid in the U.S. burn care market. The company is focused on enhancing recruitment for clinical trials and addressing regulatory requirements for manufacturing.
Read more →MDWDMediWound to Report First Quarter 2026 Financial Results
MediWound Ltd. will announce its financial results for the first quarter of 2026 on May 27th. The management will conduct a conference call and webcast at 8:30 a.m. ET to discuss these results and provide a company update. MediWound is known for its enzymatic therapies for tissue repair, including its FDA-approved product NexoBrid® and investigational therapy EscharEx®.
Read more →MDWDNewly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement
MediWound Ltd. announced the publication of a peer-reviewed consensus that redefines chronic wound debridement as a biologically active intervention. The consensus emphasizes the importance of early, less invasive treatments and supports the use of EscharEx® as a promising option for effective wound care. This aligns with MediWound's strategy to enhance chronic wound management.
Read more →MDWDMediWound to Present New EscharEx Data at Leading Wound Care Conferences
MediWound Ltd. announced that it will present new data on its EscharEx therapy at leading wound care conferences, highlighting its mechanism of action and clinical advantages. The presentations will include positive findings from a Phase III study focused on venous leg ulcers and plans for expansion into diabetic foot ulcers and pressure ulcers. New data has shown EscharEx's superiority in debridement compared to SANTYL, while supporting current and future clinical trials. The therapy is noted for its efficacy in promoting wound healing across various studies.
Read more →MDWDMediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million
MediWound Ltd. announced that Vericel Corporation has been awarded a ten-year contract by BARDA worth up to $197 million for NexoBrid. The contract includes procurement, a Vendor Managed Inventory system, and development of a new formulation. The base period of the contract is valued at $35 million, with additional optional awards for expanded procurement and clinical development.
Read more →MDWDMediWound Reports Fourth Quarter and Full Year 2025 Financial Results
MediWound Ltd. reported its financial results for Q4 and full year 2025, highlighting the progress of its Phase III VALUE trial for EscharEx and the operational status of its expanded NexoBrid manufacturing facility. Despite a decrease in revenue and an increase in operating loss, the company maintains a strong cash position and has reaffirmed its revenue guidance for the upcoming years. Key milestones are anticipated in the clinical development of EscharEx.
Read more →MDWDMediWound Files Annual Report on Form 20-F
MediWound Ltd. has filed its annual report on Form 20-F for the fiscal year ending December 31, 2025, with the U.S. SEC. The report is accessible online, and hard copies are available free to shareholders upon request. The company focuses on enzymatic therapies for tissue repair, with products like NexoBrid approved for use in various international markets and the investigational therapy EscharEx in late-stage development.
Read more →MDWDMediWound to Report Fourth Quarter and Full Year 2025 Financial Results
MediWound Ltd. has announced the upcoming release of its financial results for the fourth quarter and full year ended December 31, 2025. The report will be disclosed on March 5, 2026, followed by a conference call and live webcast hosted by the management team to discuss the highlights. MediWound is known for its pioneering enzymatic therapies, including its FDA-approved product, NexoBrid, and its investigational product, EscharEx.
Read more →MDWDMediWound to Present at Upcoming Investor Conferences
MediWound Ltd. will present at two upcoming investor conferences, the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the TDCowen 46th Annual Health Care Conference. The presentations will showcase the company's advancements in enzymatic therapeutics for tissue repair, including their FDA-approved product NexoBrid and the investigational therapy EscharEx. Webcasts of the presentations will be available for interested parties.
Read more →MDWD▼ -7.9%on this news
MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference
MediWound Ltd. provided a corporate and financial update ahead of the J.P. Morgan Healthcare Conference, highlighting their progress in clinical trials and manufacturing capabilities. The company anticipates completing enrollment for its EscharEx VALUE trial in venous leg ulcers by year-end 2026 and plans to expand the product to diabetic foot ulcers and pressure ulcers in the same year. Additionally, MediWound reported updated revenue guidance projecting significant growth in the coming years, backed by a strong cash position and operational enhancements.
Read more →MDWDMediWound Reports New Clinical Data Demonstrating NexoBrid ’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries
MediWound Ltd. has announced positive clinical data demonstrating the effectiveness of NexoBrid in preventing traumatic tattoos caused by abrasion and blast injuries. The peer-reviewed study indicated that NexoBrid achieved over a 90% reduction in pigmented wound areas. Conducted at the Sheba Medical Center, the study included 15 patients who were treated with NexoBrid within 24 hours of their injuries, showing promising results in particle removal while being well-tolerated. Despite the favorable outcomes, the study's small sample size and short follow-up period suggest the need for further investigation to confirm long-term effects.
Read more →MDWD▼ -5.6%on this news
MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update
MediWound Ltd. reported its third quarter 2025 financial results, highlighting a 23% increase in revenue year-over-year. The company completed commissioning of its expanded NexoBrid manufacturing facility and is progressing with enrollment in the VALUE Phase III trial of EscharEx. Additionally, MediWound strengthened its balance sheet through a $30 million equity financing.
Read more →MDWDMediWound to Report Third Quarter 2025 Financial Results
MediWound Ltd. will announce its financial results for the third quarter of 2025 on November 20, 2025. Following the announcement, management will host a conference call and webcast to discuss the results and provide a corporate update. The company is known for its enzymatic therapies, including the FDA-approved NexoBrid and the investigational EscharEx.
Read more →MDWDMediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid®
MediWound Ltd. has successfully completed the commissioning of its expanded GMP manufacturing facility in Yavne, Israel, which will increase production capacity for NexoBrid by sixfold. The facility is expected to be fully operational by the end of 2025, enabling the company to meet growing global demand for its product. This achievement reflects MediWound's commitment to operational excellence and timely access for patients across more than 40 approved markets.
Read more →MDWDMediWound Announces $30 Million Registered Direct Offering of Ordinary Shares
MediWound Ltd. has announced a $30 million registered direct offering of ordinary shares, led by a U.S.-based mutual fund. The offering involves 1,734,105 shares priced at $17.30 each, expected to close by September 30, 2025. Proceeds will primarily support pre-commercial activities for EscharEx and enhance manufacturing capabilities.
Read more →MDWDMediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia
MediWound Ltd. announced that Australia's Therapeutic Goods Administration has granted marketing authorization for NexoBrid, an enzymatic therapy for burn treatment. This approval allows NexoBrid to be used in both adults and children, marking its availability in 45 countries. The commercial launch in Australia is expected in Q4 2025, supported by MediWound's manufacturing expansion.
Read more →MDWDMediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress
MediWound Ltd. announced that its enzymatic burn debridement therapy, NexoBrid, will be highlighted in 36 presentations at the 21st European Burns Association Congress in Berlin. The data presented will cover various patient demographics and demonstrate NexoBrid's benefits in survival, recovery, and infection control. The therapy's superiority over surgical excision is further supported by comparative studies.
Read more →MDWDMediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference
MediWound Ltd. announced that CEO Ofer Gonen will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025. The event will be accessible via a live webcast. MediWound is known for its enzymatic therapies, including the FDA-approved NexoBrid® and the investigational EscharEx®.
Read more →MDWDMediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update
MediWound Ltd. reported a 43% revenue increase in Q2 2025, totaling $5.7 million. The company is actively enrolling patients in its VALUE Phase III trial for EscharEx® and is on track with its NexoBrid® manufacturing expansion. Additionally, MediWound has formed strategic collaborations with Essity and Convatec, enhancing its market position.
Read more →MDWDMediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers
MediWound announced new Phase II data for EscharEx, showing a significant link between wound bed preparation and closure in venous leg ulcers. The analysis involved 119 patients and highlighted the importance of complete debridement and granulation tissue coverage. These findings support EscharEx's therapeutic potential in enhancing healing outcomes for chronic wounds.
Read more →MDWDMediWound to Report Second Quarter 2025 Financial Results
MediWound Ltd. has announced it will report its financial results for the second quarter ended June 30, 2025, on August 14, 2025. The company's management will host a conference call and live webcast to discuss these results and provide corporate updates. MediWound is known for its innovative enzymatic therapies, including the FDA-approved NexoBrid for thermal burns and the investigational EscharEx for chronic wounds.
Read more →MDWDMediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update
MediWound Ltd. reported its financial results for the first quarter of 2025, highlighting ongoing progress in its key clinical and operational efforts. The company has advanced various trials, particularly the VALUE Phase III study of EscharEx for venous leg ulcers. Despite a revenue decrease, NexoBrid's demand has significantly risen, and MediWound is on track with its manufacturing expansion efforts. The company also faced an increased operating loss, raising concerns about financial sustainability amidst its ongoing investments.
Read more →MDWD▲ +6.8%on this news
MediWound Announces Publication of Phase II EscharEx Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers
MediWound Ltd. announced the publication of a post hoc analysis from its Phase II ChronEx clinical trial, demonstrating that its enzymatic therapy EscharEx is more effective than collagenase ointment (SANTYL) for treating venous leg ulcers. Key findings indicate that EscharEx showed significant improvements in complete debridement and wound bed preparation within two weeks and maintained a favorable safety profile. The company is advancing EscharEx into a global Phase III study, positioning it for potential market success in chronic wound care.
Read more →MDWDMediWound to Report First Quarter 2025 Financial Results
MediWound Ltd. announced it will report its financial results for the first quarter of 2025 on May 21, 2025. Following the release, the company's management will conduct a conference call and webcast to discuss these results and provide corporate updates. MediWound is recognized for its enzymatic therapies focused on non-surgical tissue repair, including its FDA-approved product NexoBrid and the investigational EscharEx therapy.
Read more →MDWD▼ -5.1%on this news
MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
MediWound Ltd. reported its fourth-quarter and full-year financial results for 2024, highlighting significant clinical and financial developments. The initiation of the VALUE Phase III trial for EscharEx and approval for NexoBrid in pediatric patients were notable achievements. However, the company faced increased operating and net losses compared to the prior year, raising concerns about its financial sustainability. Looking ahead, MediWound is focusing on leveraging partnerships and innovations in wound management to bolster its market presence.
Read more →MDWDMediWound to Report Fourth Quarter and Full Year 2024 Financial Results
MediWound Ltd. (Nasdaq: MDWD) has announced that it will be releasing its financial results for the fourth quarter and full year ended December 31, 2024, on March 19, 2025. Following this release, the company's management will hold a conference call and live webcast to discuss the results and provide corporate updates. MediWound is recognized for its focus on innovative biologics for tissue repair, particularly with its FDA-approved drug NexoBrid® and the promising candidate EscharEx®, which is currently in Phase III development.
Read more →MDWD▼ -7.3%on this news
MediWound Announces Phase III CIDS Publication on NexoBrid for Pediatric Burn Care
MediWound Ltd. has announced the publication of its Phase III Children Innovative Debridement Study (CIDS) for NexoBrid in the Burns journal. The study highlights NexoBrid's superiority over standard care in pediatric patients with deep thermal burns, showcasing quicker eschar removal and reduced need for surgical interventions. The findings support the drug's approved use in the U.S. and E.U. for pediatric applications, emphasizing its importance as a transformative treatment in burn care. Additionally, NexoBrid maintains a comparable safety profile with existing therapies.
Read more →MDWDMediWound to Present at the 45th Annual TD Cowen Health Care Conference
MediWound Ltd. announced that its CEO, Ofer Gonen, will present a corporate overview at the 45th Annual TD Cowen Health Care Conference on March 5, 2025, in Boston. The presentation will be available via live webcast, and a replay will be posted on the company's website. In addition to the presentation, MediWound management will be available for one-on-one meetings with interested investors. The company specializes in enzymatic therapeutics, including its FDA-approved drug NexoBrid® and the promising Phase III candidate EscharEx® for chronic wound treatment.
Read more →MDWDMediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx for Treatment of Venous Leg Ulcers
MediWound Ltd. has launched the VALUE Phase III trial aimed at evaluating EscharEx for treating venous leg ulcers (VLUs), marking the most comprehensive VLU trial in over a decade. The trial, conducted globally, will assess the efficacy and safety of EscharEx compared to placebo in 216 patients. An interim analysis is planned after 65% of the participants complete their treatments, with results expected by mid-2026. MediWound is also advancing preparations for further studies, enhancing its commercialization strategy for EscharEx.
Read more →MDWDMediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
MediWound Ltd. has announced that CEO Ofer Gonen will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025. This event will offer insights into the company's advancements in enzymatic therapeutics for tissue repair, notably their drug EscharEx, currently in Phase III trials for chronic wounds. The company aims to enhance care standards while reducing surgical needs and healthcare costs. MediWound is also engaging in one-on-one meetings with interested investors during the conference.
Read more →MDWDMediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025
MediWound Ltd. is set to host a virtual Key Opinion Leader event on January 8, 2025, to discuss the EscharEx Phase III VALUE study focused on venous leg ulcers (VLUs). The event will feature discussions from leading clinical experts and is expected to highlight EscharEx's clinical results and commercial opportunities. Additionally, the company is preparing for a Phase II/III study targeting diabetic foot ulcers (DFUs), reinforcing its commitment to innovative wound care solutions. EscharEx has shown efficacy in prior trials, with potential advantages over current competing therapies.
Read more →MDWDMediWound Reports Third Quarter 2024 Financial Results and Provides Company Update
MediWound Ltd. reported its third-quarter financial results for 2024, highlighting key achievements, including FDA approval for NexoBrid's pediatric use and progress on the Phase 3 EscharEx trial. The company anticipates $20 million in revenue for the year, lower than previous guidance due to various operational factors. Recent financing efforts, including a $25 million PIPE investment, aim to strengthen its financial position for ongoing projects. However, the company also reported increased net losses and operational costs compared to the previous year.
Read more →MDWDMediWound to Report Third Quarter 2024 Financial Results
MediWound Ltd. (Nasdaq: MDWD) announced it will report its financial results for the third quarter of 2024 on November 26, 2024. Management will hold a conference call to discuss these results and provide corporate updates. The company is known for its innovative enzymatic therapeutics, with its leading product NexoBrid receiving regulatory approvals for burn treatment. MediWound is also progressing in the market with its EscharEx, currently in Phase III trials and showing promise against existing competitors.
Read more →MDWDMediWound Announces Phase II Head-to-Head Study Evaluating EscharEx vs. Collagenase in Patients with Venous Leg Ulcers
MediWound Ltd. has announced the initiation of a Phase II clinical study to evaluate its product EscharEx compared to collagenase ointment for treating venous leg ulcers, starting in 2025. This study will run alongside a Phase III trial and aims to substantiate findings from earlier studies that indicated EscharEx's potential efficacy. Collaborations with Solventum and Mölnlycke Health Care will provide additional resources to enhance trial consistency. The study is part of MediWound's broader commercialization strategy as it prepares for a Biologics License Application submission for EscharEx.
Read more →MDWDMediWound to Participate in the 2024 Maxim Healthcare Virtual Summit
MediWound Ltd. (Nasdaq: MDWD) announced that CEO Ofer Gonen will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on October 16, 2024. The event will be hosted by Senior Biotechnology Analyst Michael Okunewitch, providing a platform for discussion on the company's advancements. MediWound is known for its next-generation enzymatic therapeutics, including its FDA and EMA-approved drug, NexoBrid®, and its potential new product, EscharEx®, currently in Phase III development. The management team will also be available for one-on-one meetings with investors during the summit.
Read more →MDWD▼ -7.3%on this news
MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference
MediWound Ltd. will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024. The CEO, Ofer Gonen, will participate in a fireside chat detailing the company's advancements in enzymatic therapeutics for tissue repair. MediWound's lead product, NexoBrid®, is approved for eschar removal in burns, with additional products like EscharEx® in development. The event underscores MediWound's position as an innovator in non-surgical treatment options and their growing R&D pipeline.
Read more →MDWDMediWound Announces U.S. Food and Drug Administration Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns
MediWound Ltd. has received FDA approval for its drug NexoBrid for use in pediatric patients with severe thermal burns, allowing eschar removal for children aged newborn through eighteen. This follows positive findings from a global Phase III trial specifically targeting pediatric patients. With this approval, NexoBrid is now authorized for use across all age groups in the U.S., in alignment with its existing approvals in Europe and Japan. MediWound is focused on advancing innovative treatments for burn care and is dedicated to reducing the trauma associated with current surgical standards.
Read more →MDWDMediWound Reports Second Quarter 2024 Financial Results and Provides Company Update
MediWound Ltd. announced its second-quarter financial results for 2024, highlighting strategic advancements and financial developments. The company has completed the construction of a new manufacturing facility and secured significant funding to accelerate the development of EscharEx for diabetic foot ulcers. Despite rising revenue attributed to Vericel, the company reported a net loss of $6.3 million, a notable decline from the previous year's profit. MediWound is well-positioned for future growth, with the upcoming Phase III study for EscharEx scheduled and an increasing market presence.
Read more →MDWD▼ -6.5%on this news
MediWound Announces Positive Results from the U.S. NexoBrid Expanded Access Protocol (NEXT)
MediWound Ltd. announced positive results from the Expanded Access Protocol (NEXT) for its product NexoBrid, aimed at providing continuous access to burn treatment. The program treated 239 patients, showing high efficacy and a favorable safety profile. Key findings included a 94.9% success rate in complete debridement for adults and no surgical excisions required for children. The results align with previous Phase III clinical trials, reinforcing NexoBrid's importance in standard burn care protocols.
Read more →MDWDMediWound to Report Second Quarter 2024 Financial Results
MediWound Ltd. (Nasdaq: MDWD) announced it will report its financial results for the second quarter of 2024 on August 14, 2024. Following the results announcement, management will host a conference call to discuss the outcomes and provide corporate updates. The company specializes in next-generation enzymatic therapeutics with a focus on non-surgical tissue repair. Among its developments is NexoBrid, an FDA and EMA-approved product for treating thermal burns, as well as EscharEx, a promising drug in its pipeline for chronic wounds.
Read more →MDWDMediWound Announces Publication of the EscharEx Phase II ChronEx Study Results for Venous Leg Ulcers
MediWound Ltd. announced the publication of the Phase II ChronEx study results for EscharEx, which showcases its efficacy in treating venous leg ulcers. The study revealed that EscharEx achieved a 63.0% incidence of complete debridement compared to 30.2% for placebo and 13.3% for non-surgical standard care. The publication in eClinicalMedicine highlights its potential as a safer, non-surgical treatment option. MediWound is preparing for a Phase III trial to further evaluate the product's effectiveness in this area.
Read more →MDWDMediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program
MediWound Ltd. (Nasdaq: MDWD) has been awarded €16.25 million in funding from the European Innovation Council Accelerator Program to support the clinical development of EscharEx, a treatment for diabetic foot ulcers. This funding will allow the company to accelerate its timelines for introducing EscharEx to the market, bringing it four years earlier than previously planned. The EIC's support emphasizes the potential impact of EscharEx on patients facing the challenges of diabetic foot ulcers, with the therapy set to address a significant unmet medical need.
Read more →MDWDMediWound Announces $25 Million Strategic Private Placement Financing
MediWound Ltd. announced a strategic financing of $25 million through a PIPE offering, selling 1,453,488 shares at $17.20 each. The gross proceeds will facilitate the development of EscharEx and strengthen the partnership with Möllycke Health Care. Alongside this financing, a collaboration agreement has been established to enhance joint efforts in wound care innovation. The PIPE Offering is expected to close soon, subject to certain customary conditions.
Read more →MDWD▼ -10%on this news
MediWound Reports First Quarter 2024 Financial Results and Provides Company Update
MediWound Ltd. reported a revenue increase to $5 million for Q1 2024, up from $3.8 million in the previous year. The company is on track to complete a new manufacturing facility by mid-2024 and plans to launch the Phase III study for EscharEx in the second half of the year. Despite these positive developments, the gross profit margin has diminished and the net loss has widened to $9.7 million. MediWound is set to be included in the Russell 3000 Index as part of its annual reconstitution.
Read more →MDWDMediWound to Report First Quarter 2024 Financial Results
MediWound Ltd. (Nasdaq: MDWD) announced it will report its financial results for the first quarter of 2024 on May 29, 2024. The company will hold a conference call and webcast at 8:30 am Eastern Time to discuss the results and provide corporate updates. MediWound is known for its specialty in enzymatic therapeutics aimed at tissue repair, with FDA-approved products like NexoBrid® for burn treatment and a promising pipeline including the Phase III-ready EscharEx® for chronic wound care.
Read more →MDWDMediWound to Present New Data from EscharEx Phase II Studies at Three Leading Wound Care Conferences
MediWound Ltd. announced it will present new clinical data from its EscharEx Phase II studies at three major wound care conferences in May 2024. The data includes comparative analyses showing EscharEx's superiority over the current leading product, SANTYL, and highlights a strong correlation between wound bed preparation and healing outcomes. Furthermore, the findings validate the planned design and endpoints for an upcoming Phase III study expected to begin in the latter half of 2024, indicating a commitment to advancing chronic wound care treatments.
Read more →MDWDMediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
MediWound Ltd. (MDWD) reported financial results for Q4 and the full year of 2023, with revenues of $19 million in 2023 and projections of $24 million for 2024. NexoBrid was commercially launched in the U.S., Japan, and India, and the company is set to begin a Phase III study of EscharEx in the latter half of 2024. Despite a decrease in revenue and operating loss in Q4 compared to the previous year, noteworthy advances in product development and significant R&D funding were highlighted as positives.
Read more →MDWDMediWound to Report Fourth Quarter and Full Year 2023 Financial Results
MediWound Ltd. (Nasdaq: MDWD) announced it will release its financial results for Q4 and full year 2023 on March 21, 2024. Following the release, management will conduct a conference call to discuss the results and corporate updates. The company, known for its innovations in non-surgical tissue repair, has a promising pipeline including EscharEx®, which is phase III-ready, and MW005 for basal cell carcinoma treatment.
Read more →MDWDMediWound Announces Positive Results in Head-to-Head Comparison of EscharEx vs. SANTYL within the ChronEx Phase II Randomized Controlled Study
MediWound Ltd. announced positive results from a head-to-head comparison of its lead product, EscharEx, against the market-leading SANTYL in a Phase II study focused on chronic wounds. The results highlighted EscharEx's superior efficacy, achieving complete debridement in 63% of patients compared to 0% for SANTYL. MediWound's CEO expressed optimism for EscharEx becoming a market leader and they plan to initiate a Phase III trial in the second half of 2024. These findings are expected to be presented at major wound care congresses in May 2024.
Read more →MDWD▼ -8.7%on this news
MediWound to Participate in Two Upcoming Investor Conferences
MediWound Ltd. (Nasdaq: MDWD) has announced its participation in two upcoming investor conferences: the Oppenheimer 34th Annual Life Sciences Conference and the TD Cowen 44th Annual Health Care Conference. The virtual conference will take place from February 13-14, 2024, while the Boston event occurs from March 4-6, 2024. During these conferences, the management team will host one-on-one meetings with interested investors, highlighting their commitment to growth and engagement in the investment community.
Read more →MDWD▲ +5.7%on this news
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
MediWound Ltd. announced that the FDA has accepted for review its supplemental Biologics License Application (sBLA) for NexoBrid, aiming to include pediatric patients with severe thermal burns. This follows the drug's successful approval for adult patients in December 2022. The sBLA is backed by results from the Children Innovation Debridement Study (CIDS) and other pediatric studies, signifying an important step in expanding treatment options. MediWound expresses commitment to innovate the standard of care for severe burn treatments across all ages.
Read more →MDWDMediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid Development for the U.S. Army
MediWound Ltd. has announced the receipt of an additional $6.7 million in funding from the U.S. Department of Defense to advance the development of NexoBrid, aiming to improve burn treatment for the U.S. Army. The funding will help facilitate the establishment of a GMP compliant production line for a new temperature-stable formulation of NexoBrid, enhancing its readiness for military use. The project underscores MediWound's commitment to providing effective medical solutions for severe burn injuries in field-care settings.
Read more →MDWDMediWound Announces Peer-Reviewed Publication of EscharEx Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads
MediWound Ltd. announced the publication of a peer-reviewed study detailing the effects of EscharEx on biofilm and microbial loads in chronic wounds. The Phase II study involved 12 patients, showing that 70% achieved complete debridement within 5.5 days and 100% of biofilm-positive patients had significant reductions by the end of treatment. The findings suggest EscharEx could potentially expedite healing processes in chronic wounds and reduce the risk of severe complications. The company plans to initiate a Phase III pivotal study in late 2024.
Read more →MDWDMediWound Reports Third Quarter 2023 Financial Results and Provides Company Update
MediWound Ltd. reported its financial results for the third quarter of 2023, highlighting a successful launch of NexoBrid in both the U.S. and Japan. The company has prioritized resources to meet the increased global demand for NexoBrid, driven in part by funding from the U.S. Department of Defense. Despite a decrease in revenues compared to the previous year, the company is optimistic about its future growth, particularly with advancements in its EscharEx Phase III study preparations. Furthermore, MediWound has strengthened its corporate structure with the appointment of Shmulik Hess as COO and CCO.
Read more →MDWDMediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer
MediWound Ltd. has appointed Dr. Shmulik Hess as Chief Operating Officer and Chief Commercial Officer, effective December 1, 2023. Dr. Hess brings over two decades of experience in the biopharma industry and will lead both operational and commercial activities at the company. This appointment comes during a critical phase of expansion as MediWound aims to scale its production capabilities and advance its product pipeline, including the FDA-approved NexoBrid and the development-stage EscharEx. The CEO expressed confidence in Dr. Hess's qualifications to drive the company's global strategy and evolution.
Read more →MDWDMediWound to Report Third Quarter 2023 Financial Results
MediWound Ltd. (Nasdaq: MDWD) announced it will release its third-quarter financial results for the period ending on September 30, 2023, on November 21, 2023. Following the results announcement, the management will host a conference call and live webcast to discuss the financial outcomes and corporate updates. MediWound specializes in next-generation enzymatic therapeutics aimed at non-surgical tissue repair, boasting an FDA-approved product and a robust R&D pipeline.
Read more →MDWDMediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid to Treat Pediatric Patients
MediWound Ltd. has announced that the CHMP of the EMA issued a positive opinion recommending the marketing authorization for NexoBrid to be expanded to include pediatric patients. The decision is based on results from a Phase 3 trial demonstrating significant safety and efficacy in treating deep thermal burns in children. The positive outcome marks a potential shift in burn treatment, presenting a non-surgical option that reduces trauma for young patients. A final decision by the European Commission is anticipated soon.
Read more →MDWDMediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid Distribution in Europe
MediWound Ltd. has formed a collaboration agreement with PolyMedics Innovations to promote NexoBrid in Germany, Austria, Belgium, the Netherlands, and Luxembourg. The partnership aims to leverage PMI's extensive commercial resources to enhance the utilization of NexoBrid, a non-surgical treatment for eschar removal in burn patients. With NexoBrid approved in over 40 countries, this collaboration is expected to improve patient care and broaden its accessibility in Europe.
Read more →MDWDMediWound Announces Collaboration with 3M on EscharEx Phase III Study
MediWound Ltd. has announced a collaboration with 3M Health Care to utilize their two-layer compression systems during the Phase III study of EscharEx, a treatment for chronic wounds. The study aims to evaluate the efficacy and safety of EscharEx for debridement in patients with venous leg ulcers. This partnership is expected to enhance patient care and provide reliable data on the clinical advantages associated with the compression systems. MediWound's EscharEx enters the Phase III study with positive momentum from previous Phase 2 trials.
Read more →MDWDMediWound Deploys NexoBrid for Emergency Supply
MediWound Ltd. has responded to the urgent demand for its burn treatment NexoBrid following the war in Israel, deploying all available inventory to assist hospitals and military forces. NexoBrid, which enzymatically removes nonviable burn tissue, is approved in over 40 countries and supported by the U.S. Biomedical Advanced Research and Development Authority. MediWound remains dedicated to maintaining supply for global markets while focusing on its pipeline of other innovative products.
Read more →MDWDMediWound Announces U.S. Commercial Availability of NexoBrid for the Treatment of Severe Thermal Burns in Adults
MediWound Ltd. announced the U.S. commercial availability of NexoBrid for treating severe thermal burns in adults. NexoBrid offers a non-surgical method for eschar removal, preserving viable tissue and potentially reducing the need for skin grafts. The company emphasizes the importance of providing innovative treatment solutions for burn patients. NexoBrid also represents a significant market opportunity, with over 40,000 hospitalizations for burn injuries in the U.S. annually.
Read more →MDWD▲ +6.8%on this news· ran to +25% by day 3
MediWound’s NexoBrid Highlighted in 20 Oral and Poster Presentations at the 20th European Burns Association Congress
MediWound Ltd. participated in the 20th European Burns Association Congress where its product NexoBrid was highlighted in 20 oral and poster presentations. These presentations were made by leaders in burn care, showcasing patient outcomes and applications for NexoBrid in various settings. The company expressed its delight over the extensive feature of NexoBrid, emphasizing its commitment to advancing global burn care through research and collaboration with specialists.
Read more →MDWDMediWound to Participate in Fireside Chat at H.C. Wainwright 25th Annual Global Investment Conference
MediWound Ltd. (Nasdaq: MDWD) will participate in the H.C. Wainwright 25th Annual Global Investment Conference from September 11-13, 2023. CEO Ofer Gonen will engage in a fireside chat on September 13. The company is known for its next-generation enzymatic therapeutics, including its FDA-approved drug NexoBrid® and the Phase III candidate EscharEx®. MediWound is committed to improving patient outcomes while reducing costs and complications related to surgical interventions.
Read more →MDWDMediWound Announces Collaboration with MIMEDX on EscharEx Phase III Study
MediWound Ltd. has announced a collaboration with MIMEDX Group, Inc. for a Phase III study of its EscharEx treatment targeting venous leg ulcers (VLUs). The study will utilize MIMEDX's EPIFIX allograft to standardize treatment during the wound healing process, a crucial factor emphasized by the FDA. This collaboration marks a significant milestone, as it represents the largest VLU study conducted in the past decade, aiming to provide critical insights into advanced wound care. EscharEx, designed to enzymatically debride chronic wounds, has previously shown promise in Phase II studies and is expected to transition into global trials in early 2024.
Read more →MDWDMediWound Reports Second Quarter 2023 Financial Results and Provides Company Update
MediWound Ltd. reported its second-quarter financial results and updates regarding its product pipeline. The company announced significant progress on its EscharEx Phase III study, with patient enrollment anticipated to start in early 2024. While the U.S. launch of NexoBrid is delayed due to complications at a third-party lab, revenues for 2023-2024 are not expected to be affected. The company also received an additional $10 million in funding from BARDA and launched NexoBrid in Japan.
Read more →MDWDMediWound to Report Second Quarter 2023 Financial Results
MediWound Ltd. (Nasdaq: MDWD) announced the upcoming release of its second quarter financial results for 2023, scheduled for August 15, 2023. Following the announcement, management will host a conference call at 8:30 am ET to discuss the results and provide corporate updates. The company continues to lead in enzymatic therapeutics with a robust pipeline aimed at improving patient outcomes in tissue repair and chronic wound management.
Read more →MDWDMediWound Announces Commercial Launch of NexoBrid in Japan
MediWound Ltd. has announced the commercial launch of its product NexoBrid in Japan, through its strategic partnership with Kaken Pharmaceutical. This topical treatment is designed for the removal of eschar in patients with deep partial and full-thickness burns. NexoBrid replaces traditional surgical methods with a single 4-hour treatment, making it a potentially significant advancement in the burn care market. Both companies emphasize the importance of this launch in a key healthcare market where over 6,000 patients are treated for severe burns annually.
Read more →MDWDMediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
MediWound Ltd. announced positive results from its Phase I/II study of MW005 for treating low-risk Basal Cell Carcinoma (BCC), indicating that MW005 is both safe and well-tolerated. Out of 15 patients treated, 11 achieved complete clinical and histological clearance of their lesions. These findings provide proof-of-concept for MW005 as a potential non-surgical treatment option for BCC, addressing a significant unmet medical need. The results will be presented at an upcoming scientific conference in 2023, supporting further investigation of MW005 in larger studies.
Read more →MDWDMediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design
MediWound Ltd. has received positive scientific advice from the EMA regarding its Phase III study design for EscharEx, a treatment for venous leg ulcers (VLUs). The CHMP has approved the study's design, noting that a single confirmatory study could suffice for marketing authorization if the data is robust. The global, placebo-controlled trial will involve around 244 patients, focusing on the effectiveness of EscharEx in achieving wound closure. This development signifies a potential advancement in therapies for chronic wounds, impacting a significant patient population annually.
Read more →MDWDMediWound to Participate in Fireside Chat at Maxim Group Healthcare Virtual Conference 2023
MediWound Ltd. (Nasdaq: MDWD) announced its participation in the Healthcare Virtual Conference Part II hosted by Maxim Group from June 20 to June 22, 2023. CEO Ofer Gonen will engage in a fireside chat with Senior Research Analyst Michael Okunewitch on June 20 at 9:30am ET. MediWound focuses on enzymatic therapeutics for non-surgical tissue repair, with several promising developments in its pipeline, including the Phase III study of its lead drug, EscharEx, expected to start in Q4 2023.
Read more →MDWD▼ -7.5%on this news
MediWound Reports First Quarter 2023 Financial Results and Provides a Company Update
MediWound Ltd. reported their financial results for the first quarter of 2023, highlighting key developments including plans to initiate a Phase III study for EscharEx in the fourth quarter. The company is set to launch NexoBrid in the U.S. by early third quarter 2023 and has a robust cash position with over $57 million available. Despite a year-over-year decline in total revenues and increased operating losses, the company's advancements signify a strong trajectory in addressing unmet medical needs.
Read more →MDWDMediWound to Report First Quarter 2023 Financial Results
MediWound Ltd. (Nasdaq: MDWD) will release its financial results for the first quarter ended March 31, 2023, on May 30, 2023. Following the release, management will host a conference call at 8:30 am ET to discuss the results and provide corporate updates. MediWound is known for its enzymatic therapeutics aimed at non-surgical tissue repair, including the FDA-approved NexoBrid and the upcoming Phase III study for EscharEx.
Read more →MDWDMediWound Announces an Additional $10 Million Award from BARDA
MediWound Ltd. announced a $10 million award from BARDA to support its ongoing development of NexoBrid, focusing on pediatric burn indications. The funding will replenish emergency stockpiles and facilitate patient enrollment in expanded access protocols. NexoBrid aims to provide a non-surgical option for burn treatment, particularly benefiting pediatric patients. The combined funding from BARDA has now reached up to $216 million, underscoring the significance of NexoBrid in emergency preparedness and patient care.
Read more →MDWDMediWound to Present Phase 2 EscharEx Data at the Symposium on Advanced Wound Care (SAWC) Spring 2023
MediWound Ltd. announced that it will present updated clinical data from its EscharEx Phase 2 trials at the 2023 Symposium on Advanced Wound Care (SAWC). The presentations will include both oral and virtual posters, showcasing the treatment experience and results from studies on chronic wound management. CEO Ofer Gonen expressed optimism about EscharEx's potential to be a leading enzymatic debridement solution, highlighting its promising outcomes. The event will feature discussions from key opinion leaders and is anticipated to connect experts in wound care to advance patient outcomes.
Read more →MDWDMediWound Reports Fourth Quarter and Full Year 2022 Financial Results and Company Update
MediWound Ltd. has reported positive financial results for the fourth quarter and full year 2022, highlighting a total revenue of $26.5 million. The company received FDA approval for its product NexoBrid in December 2022, with U.S. commercial availability expected in mid-2023. MediWound's cash position stands at $66 million, which includes funds raised through equity offerings and milestone payments. However, the company also reported a net loss of $19.6 million for the year, largely due to non-cash financial expenses.
Read more →MDWDMediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer
MediWound Ltd. has appointed Hani Luxenburg as its new Chief Financial Officer, effective May 14, 2023. She succeeds Boaz Gur-Lavie, who will remain until July 31, 2023, to ensure a smooth transition. Luxenburg brings over 20 years of relevant financial leadership experience, including her recent role at BIRD Aerosystems and previous positions at AstraZeneca and Ernst & Young. The company looks to leverage her expertise to support its strategic objectives and the upcoming U.S. launch of its product NexoBrid.
Read more →MDWDMediWound Expands its Global Leadership Team to Help Drive Company’s Future Growth
MediWound Ltd. has announced key appointments to its global leadership team, naming Barry Wolfenson as Executive Vice President of Strategy and Corporate Development, and Alicia Torrenova as Vice President of European Operations. Both leaders bring over 20 years of experience in wound care and regenerative medicine, which is expected to drive the company's strategic initiatives and growth. MediWound is focused on developing innovative biotherapeutic solutions for tissue repair and regeneration, showcasing its commitment to enhancing patient care through advanced technology.
Read more →MDWDMediWound to Report Fourth Quarter and Year-End 2022 Financial Results
MediWound Ltd. (Nasdaq: MDWD) will release its financial results for the fourth quarter and year ended December 31, 2022, on March 16, 2023. Following this announcement, the company will host a conference call to discuss the financial outcomes and provide corporate updates. MediWound is focused on biotherapeutic solutions for tissue repair and regeneration, with prospects for products like EscharEx and MW005 showing positive development in trials. This reporting reflects the company's commitment to innovation and market expansion.
Read more →MDWDMediWound to Present Corporate Highlights at Upcoming Investor Conferences
MediWound Ltd. announced it will present corporate highlights at two investor conferences in March 2023. The company focuses on biotherapeutic solutions for tissue repair and regeneration. Its product NexoBrid has received FDA approval for marketing in the United States, while other products like EscharEx have shown promising results in clinical trials. MediWound continues to demonstrate commitment to innovation and improving patient care through its therapies.
Read more →MDWDMediWound Announces Closing of $27.5 Million Registered Direct Offering of Ordinary Shares
MediWound Ltd. recently announced the closing of a $27.5 million registered direct offering of ordinary shares. The company intends to utilize the proceeds primarily to expedite the development of EscharEx and establish a commercial presence in the U.S. MediWound has also indicated potential uses for the funds in acquiring technologies or businesses that complement its current operations. The company is actively pursuing discussions with the FDA regarding the pivotal Phase 3 study design for EscharEx.
Read more →MDWDMediWound Announces $27.5 Million Registered Direct Offering of Ordinary Shares Priced At-The-Market
MediWound Ltd. announced a registered direct offering of 1,964,286 ordinary shares priced at $14 each, expected to raise about $27.5 million. The proceeds will primarily focus on advancing the development of its product EscharEx, establishing a U.S. commercial presence, and overall corporate purposes. The company is currently engaged in expanding its product portfolio and has shown positive results in clinical trials for both EscharEx and MW005.
Read more →MDWDMediWound Announces FDA Approval of NexoBrid for the Treatment of Severe Thermal Burns in Adults
Potential to become the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns Triggers $7.5 million milestone payment from Vericel Corporation; NexoBrid is anticipated to be commercially available in the U.S. in the second qu
Read more →MDWD▲ +5%on this news· ran to +22% by day 3shared move
MediWound Expands NexoBrid’s Global Presence with Marketing Approval in Japan
Japan is the first country in the world to approve NexoBrid for people of all ages; pediatric and adult populations Exclusive marketing and distribution agreement with Kaken Pharmaceutical Co., Ltd. YAVNE, Israel, Dec. 23, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD),
Read more →MDWD▲ +17.7%on this newsshared move
MediWound Strengthens European Presence of NexoBrid
NexoBrid gained marketing approval in Switzerland; launch expected first quarter 2023 Launch in France expected in third quarter 2023 YAVNE, Israel, Dec. 20, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-gen
Read more →MDWD▼ -7.6%on this newsshared move
MediWound Announces Positive Results in U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
MW005 shown to be safe and well-tolerated Data provides clinical efficacy proof-of-concept based on complete clearance of target lesions YAVNE, Israel, Dec. 19, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company,
Read more →MDWDMediWound Expands Global Presence as NexoBrid Gains Approval in India
YAVNE, Israel, Dec. 13, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced it has gained marketing approval of NexoBrid® in In
Read more →MDWD▼ -5.8%on this news· ran to -16% by day 3
MediWound Announces a 1-for-7 Reverse Share Split
YAVNE, Israel, Dec. 05, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound” or the “Company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that it intends to e
Read more →MDWD▲ +15.2%on this news
MediWound Reports Third Quarter 2022 Financial Results and Provides Company Update
$30.5 million in gross proceeds raised; operating cash runway through 2025 NexoBrid PDUFA date of January 1, 2023; Upon approval, NexoBrid expected to generate meaningful revenues Company focused on the billion-dollar market opportunity with EscharEx Phase 3 clinical study to b
Read more →MDWD▼ -6.4%on this news
MediWound’s EscharEx Featured in Paper as a Potential Paradigm Shift Towards Non-Surgical Wound Bed Preparation in DFUs
Paper published in the November 2022 issue of Podiatry Management (Robert J. Snyder, DPM, Cyaandi Dove, DPM, and Vickie Driver, DPM, MS) YAVNE, Israel, Nov. 09, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-
Read more →MDWDMediWound to Report Third Quarter 2022 Financial Results
YAVNE, Israel, Nov. 03, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results
Read more →MDWDMediWound Announces Formation of Strategic Advisory Board
YAVNE, Israel, Oct. 25, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the establishment of a Strategic Advisory Board (SA
Read more →MDWD▲ +10.7%on this news
MediWound's EscharEx Featured in Oral and Poster Presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2022
YAVNE, Israel, Oct. 18, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that positive clinical data from the Company’s Esch
Read more →MDWDMediWound Announces Closing of the Concurrent Registered Direct and Private Placement Offerings
YAVNE, Israel, Oct. 07, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the closing of its previously announced registered
Read more →MDWD▼ -22.9%on this news
MediWound Announces Concurrent Registered Direct and Private Placement Offerings Priced At-the-Market of Approximately $30 Million
YAVNE, Israel, Sept. 22, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) (the “Company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that it has entered into a definit
Read more →MDWDMediWound’s NexoBrid Highlighted in 45 Posters and Presentations at the 19th European Burns Association Congress
YAVNE, Israel, Sept. 12, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced its successful and meaningful presen
Read more →MDWDMediWound Reports Second Quarter 2022 Financial Results and Provides Company Updates
Positive Results in Two Phase 2 Trials of EscharEx FDA Assigned PDUFA Target Date of January 1, 2023 for NexoBrid BLA Enhanced the Board and Leadership Team Conference Call Begins Today at 8:30 AM Eastern Time YAVNE, Israel, Aug. 09, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (N
Read more →MDWDMediWound Enhances Its Board and Executive Leadership Team
Mr. Nachum Shamir appointed as Chairman of the Board Dr. Robert Snyder appointed as Chief Medical Officer YAVNE, Israel, Aug. 08, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biot
Read more →MDWDMediWound Announces U.S. FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns
YAVNE, Israel, Aug. 03, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the U.S. Food and Drug Administr
Read more →MDWDMediWound Schedules Second Quarter 2022 Financial Results
Call Scheduled for Tuesday, August 9, 2022 at 8:30 AM Eastern Time YAVNE, Israel, Aug. 01, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration,
Read more →MDWDMediWound Announces Positive Initial Data from its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
MW005 Shown to Be Safe and Well-Tolerated Target Lesions Clearance Data Provides Clinical Efficacy Proof-of-Concept YAVNE, Israel, July 11, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-gene
Read more →MDWDMediWound Announces Presentation on EscharEx at the Advanced Wound Care Summit in Boston on July 13
YAVNE, Israel, July 08, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced an oral presentation at the Advanced Wound Care Sum
Read more →MDWDMediWound Announces Positive Results from its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg Ulcers
EscharEx Showed Safe, Effective and Rapid Debridement in VLUs and DFUs Data Demonstrates EscharEx Reduced Wound Size, Biofilm and Bacterial Burden YAVNE, Israel, July 07, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutica
Read more →MDWDMediWound to Host a Key Opinion Leader Investor Day on EscharEx
YAVNE, Israel, July 05, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that it will host an in-person key opinion leader (
Read more →MDWDMediWound Names Mr. Tzvi Palash as Chief Operating Officer
YAVNE, Israel, June 30, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the appointment of Mr. Tzvi Palash as Chief Operati
Read more →MDWD▼ -6.3%on this news
MediWound Announces CEO Transition
Ofer Gonen, current Board member and CEO of Clal Biotechnology Industries Ltd., appointed as New CEO – Effective June 30 Will replace current CEO Sharon Malka, who will join the Board of Directors YAVNE, Israel, May 17, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a
Read more →MDWD▼ -6.3%on this news
MediWound Reports First Quarter 2022 Financial Results
Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds On track for NexoBrid BLA resubmission by mid-year Conference Call Begins Today at 8:30 am ET YAVNE, Israel, May 17, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully-integ
Read more →MDWD▲ +6.1%on this newsshared move
MediWound Announces Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds
Study Met Primary and Key Secondary Endpoints with Statistically Significant Results Compared to Control Arms Significant Improvement Across Multiple Measures Over the Current Non-Surgical Standard-of Care No Deleterious Effect on Wound Closure and No Observed Safety Issues En
Read more →MDWD▲ +7.4%on this newsshared move
MediWound to Report First Quarter Financial Results and Host a Conference Call and Webcast on May 17, 2022
YAVNE, Israel, May 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results
Read more →MDWDMediWound's EscharEx Highlighted in Poster and Oral Presentation at the Symposium on Advanced Wound Care (SAWC) Spring 2022
YAVNE, Israel, April 12, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that clinical data from the Company’s EscharEx® ph
Read more →MDWD▲ +5.4%on this news
MediWound to Present EscharEx Clinical Data at the Symposium on Advanced Wound Care (SAWC) Spring 2022
Results Highlight the Safety and Efficacy in Hard-to-Heal Wounds SAWC to Take Place in Phoenix, Arizona on April 6-10, 2022 YAVNE, Israel, March 29, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation b
Read more →MDWDMediWound Announces Exercise of Over-Allotment Option
YAVNE, Israel, March 22, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration, today announced that the
Read more →MDWDMediWound Announces Last Patient Out in EscharEx U.S. Phase 2 Trial for the Debridement of Chronic Wounds
Primary Endpoint Met with Highly Statistically Significant Results Final Data Readout Expected in Second Quarter of 2022 YAVNE, Israel, March 21, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biot
Read more →MDWDMediWound Reports Fourth Quarter and Full Year 2021 Financial Results
Full-Year 2021 Total Revenues of $23.8 Million; Product Revenues Up 46% Positive Top-Line Data for EscharEx Phase 2 Clinical Trial, with Full Data Set Anticipated in Second Quarter 2022 Raised Gross Proceeds of $10 Million through Public Equity Offering Conference Call Begins
Read more →MDWDMediWound Announces Closing of Public Offering of Ordinary Shares
YAVNE, Israel, March 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration, today announced that on M
Read more →MDWDMediWound to Report Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call and Webcast on March 17, 2022
YAVNE, Israel, March 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial resul
Read more →MDWD▼ -14.2%on this news
MediWound Announces Pricing of Public Offering of Ordinary Shares
YAVNE, Israel, March 03, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration, today announced the prici
Read more →MDWD▼ -6.2%on this news· ran to -20% by day 3shared move
MediWound Ltd. Announces Proposed Public Offering of Ordinary Shares
YAVNE, Israel, March 02, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“Mediwound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration, today announced that it i
Read more →MDWDMediWound to Present at Upcoming Investor Conferences in March
YAVNE, Israel, March 01, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that management would present at two upcoming inve
Read more →MDWDMediWound Awarded a U.S. Department of Defense Research Grant for the Development of NexoBrid for the U.S. Army
YAVNE, Israel, Feb. 17, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio therapeutic solutions for tissue repair and regeneration, today announced that the U.S. Department of Defense (DoD), through
Read more →MDWDMediWound to Present at Upcoming Investor Conferences in February
YAVNE, Israel, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that management would present at two upcoming inves
Read more →MDWD▲ +5%on this newsshared move
MediWound Announces Additional $9 Million in Funding from BARDA to Support NexoBrid BLA Resubmission and the Expanded Access Treatment Protocol
YAVNE, Israel, Feb. 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the Biomedical Advanced Research and Developme
Read more →MDWDMediWound Announces Positive Topline Results From Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds
Primary Endpoint Met with Highly Statistically Significant Results No Observed Safety Issues Final Data Readout Expected in Second Quarter of 2022 YAVNE, Israel, Jan. 24, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focus
Read more →MDWDMediWound Announces Positive Initial Data from its U.S. Phase 2 Pharmacology Study of EscharEx Showing Effective and Rapid Debridement in Chronic and Hard to Heal Wounds
Data Demonstrate EscharEx Reduces Biofilm and Bacterial Burden EscharEx is Shown to be Safe with No Observed Safety Issues YAVNE, Israel, Dec. 20, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on nex
Read more →MDWDMediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study
YAVNE, Israel, Dec. 06, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced it has completed patient enrollment
Read more →MDWD▼ -7.4%on this news
MediWound Reports Third Quarter 2021 Financial Results
Third Quarter Revenues of $6.4 Million; Year-to-Date 2021 Revenues Increased 21% Clarity on Regulatory Pathway for Resubmission of NexoBrid BLA, Anticipated in Mid- 2022 EscharEx Phase 2 Program Top-Line Results Accelerated, Currently Expected in the First Quarter of 2022 Conf
Read more →MDWDMediWound to Report Third Quarter 2021 Financial Results and Host a Conference Call and Webcast on November 16, 2021
YAVNE, Israel, Nov. 04, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial result
Read more →MDWDMediWound Announces Peer-Reviewed Publication of EscharEx In-Vivo Head-to-Head Comparator Study in the Journal of Wound Care
YAVNE, Israel, Oct. 04, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced a peer-reviewed publication in the Journal of Woun
Read more →MDWDMediWound Reports Second Quarter Financial Results
Second Quarter Revenues of $6.1 Million - Increase of 50% Year-over-Year Positive Interim Assessment Outcome for EscharEx U.S. Phase II Clinical Study No Changes to Study Sample Size – No Safety Concerns Identified Conference call begins today at 8:30 am ET YAVNE, Israel, Aug
Read more →MDWDMediWound to Report Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 10, 2021
YAVNE, Israel, Aug. 02, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial result
Read more →MDWDMediWound Announces Positive Outcome of Interim Assessment for its EscharEx U.S. Phase 2 Adaptive Design Study
Independent Data Monitoring Committee Recommends Continuation of the Study with No Changes to Study Sample Size No Safety Concerns Identified Full Study Enrollment Expected by Year-End 2021; Data Readout Expected in the First Half of 2022 YAVNE, Israel, July 28, 2021 (GLOBE N
Read more →MDWDMediWound Announces Initiation of U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
Data Expected End of 2021 Phase II Investigator-Initiated Trial in Non-Melanoma Skin Cancers Running in Parallel YAVNE, Israel, July 26, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeut
Read more →MDWDMediWound Announces Positive Topline Results from Phase 3 Pediatric Study (CIDS) of NexoBrid for Eschar Removal of Severe Thermal Burns
YAVNE, Israel, July 20, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair and regeneration, today announced positive topline results from its pivotal phase 3
Read more →MDWDMediWound Announces Peer-Reviewed Paper Detailing EscharEx Phase 2 Randomized Control Trial Results Published in the Online Wound Repair and Regeneration Journal
Study Findings Demonstrate Strong Results in Debriding Venous Leg Ulcers and Diabetic Foot Ulcers Interim Assessment of Ongoing U.S. Phase II Adaptive Design Study in Venus Leg Ulcers Expected End of July 2021 YAVNE, Israel, July 09, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nas
Read more →MDWDMediWound Receives Complete Response Letter from U.S. FDA for NexoBrid Biologics License Application
YAVNE, Israel, June 29, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair and regeneration, today announced it received a Complete Response Letter (CRL) from
Read more →MDWDMediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design Study
YAVNE, Israel, June 09, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the enrollment target of patients for an inter
Read more →MDWDMediWound Announces Peer-Reviewed Paper of a Case Series Report of Basal Cell Carcinoma Published in the Open Dermatology Journal
Findings Provide Preliminary Proof-of-Concept Phase I/II Clinical Study in Basal Cell Carcinoma Scheduled to Begin in Second Quarter 2021, with Data Expected by the End of 2021 YAVNE, Israel, June 07, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated bi
Read more →MDWDMediWound Reports First Quarter 2021 Financial Results
First Quarter Revenues of $5.8 Million, an Increase of 32% Year-over-Year Conference call begins today at 8:30 am ET YAVNE, Israel, May 05, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therap
Read more →MDWDMediWound to Report First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 5, 2021
YAVNE, Israel, April 26, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial resul
Read more →MDWDMediWound Enrolls First Patient in Phase 2 Pharmacology Study of EscharEx
YAVNE, Israel, April 22, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair and regeneration, today announced it has enrolled the first patient in its phase 2
Read more →MDWDMediWound Hosting Analyst Day Webinar on EscharEx – Enzymatic Debridement Agent for Chronic Wounds
YAVNE, Israel, March 24, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that it will host an analyst day webinar on Escha
Read more →MDWDMediWound to Participate in Upcoming March Investment Conferences
YAVNE, Israel, Feb. 25, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will present at the following vir
Read more →MDWDMediWound Reports Fourth Quarter and Full-Year 2020 Financial Results
Fourth Quarter Revenues of $6.7 Million - Up 23% and Full-Year 2020 Revenues of $21.8 Million - Product Revenue Up 117% Conference call begins today at 8:30 am ET YAVNE, Israel, Feb. 25, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutic
Read more →MDWDMediWound Launches Clinical Development Program for Treatment of Non-Melanoma Skin Cancer
Phase I/II Clinical Study in Basal Cell Carcinoma Scheduled to Begin Second Quarter 2021, with Data Expected by the End of 2021 An Investigator-Initiated Trial Will Run in Parallel YAVNE, Israel, Feb. 22, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrate
Read more →MDWDMediWound to Report Fourth Quarter and Fiscal 2020 Financial Results and Host a Conference Call and Webcast on February 25, 2021
YAVNE, Israel, Feb. 16, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial resul
Read more →MDWDMediWound to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
YAVNE, Israel, Feb. 10, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Sharon Malka, Chief Executive Officer, will
Read more →MDWDMediWound Provides Progress Update on Its EscharEx Clinical Development Program
Phase 2 Adaptive Design Study Sample Size Reduced to 120 Patients Interim Assessment Expected in Mid-2021 and Completion of Enrollment by Year-End 2021 Protocol Submitted to FDA for Pharmacology Clinical Study with Data Expected in Second Half 2021 YAVNE, Israel, Jan. 11, 2021
Read more →MDWDMediWound to Participate in Upcoming Investor Conferences in January
YAVNE, Israel, Jan. 05, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that it will participate in the forthcoming LifeS
Read more →MDWDMediWound Continues Global Expansion with Distribution Agreement for NexoBrid in United Arab Emirates with Ghassan Aboud Group
YAVNE, Israel, Dec. 14, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced it has further expanded its NexoBrid® global pres
Read more →MDWDMediWound Reports Third Quarter 2020 Financial Results
Total Third Quarter Revenues of $6.6 Million Increased 29% Year-over-Year Assigned PDUFA Goal Date of June 29, 2021 for NexoBrid BLA YAVNE, Israel, Nov. 10, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative
Read more →MDWDMediWound to Report Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 10, 2020
YAVNE, Israel, Nov. 02, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial resul
Read more →MDWDMediWound Completes Enrollment Stage of its NexoBrid Phase 3 Pediatric Study
YAVNE, Israel, Oct. 28, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced it has completed the enrollment stage of its Nexo
Read more →MDWDMediWound Studying the Effect of EscharEx on Biofilm Burden
YAVNE, Israel, Oct. 14, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) ("MediWound”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that it is exploring the pharmacolo
Read more →MDWDMediWound Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns
YAVNE, Israel, Sept. 16, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “MediWound”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the U.S. Food and Drug Ad
Read more →MDWDMediWound to Present at Upcoming Investor Conferences in September
YAVNE, Israel, Sept. 03, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Sharon Malka, MediWound’s C
Read more →MDWDMediWound and Vericel Announce Acceptance of the First Delivery of NexoBrid to BARDA for Emergency Response Preparedness
YAVNE, Israel and CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) and its U.S. commercial partner Vericel Corporation (NASDAQ: VCEL) today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of th
Read more →MDWDMediWound Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Submitted Biological License Application to the FDA for NexoBrid EscharEx U.S. Phase 2 Study Resumed Patient Screening YAVNE, Israel, Aug. 06, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovativ
Read more →MDWDMediWound to Report Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on August 6, 2020
YAVNE, Israel, July 28, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial resul
Read more →MDWDMediWound Announces Submission of Biologics License Application to the U.S. FDA for NexoBrid for the Treatment of Severe Thermal Burns
YAVNE, Israel, June 30, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet medical needs in severe burn and wound management, today announced it has submitted a Biologics License Appl
Read more →MDWDMediWound Reports First Quarter 2020 Financial Results and Provides Corporate Update
YAVNE, Israel, May 20, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced financial results for the first qu
Read more →MDWDMediWound to Report First Quarter 2020 Financial Results and Host a Conference Call and Webcast on May 20, 2020
YAVNE, Israel, May 13, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial result
Read more →MDWDMediWound Strengthens its NexoBrid European Presence with Additional Distribution Agreements
YAVNE, Israel, May 04, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet medical needs in severe burn and wound management, today announced the expansion of its NexoBrid® European pr
Read more →MDWDMediWound Strengthens Board of Directors
YAVNE, Israel, April 27, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the appointments of Mr. Samuel Moed and Mr. Davi
Read more →MDWDMediWound Provides Corporate Update Related to COVID-19 Pandemic
YAVNE, Israel, March 30, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today provided an update on certain impacts of t
Read more →MDWDMediWound to Present at Cowen and Company 40th Annual Healthcare Conference
YAVNE, Israel, Feb. 28, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Sharon Malka, MediWound’s Chief Executive Of
Read more →MDWDMediWound Reports Fourth Quarter and Full-Year 2019 Financial Results
Generated total full-year 2019 revenues of $31.8 million, driven primarily by Vericel license payment and development services to BARDA Initiated U.S. Phase 2 adaptive design study of EscharEx for the treatment of venous leg ulcers BARDA initiated the procurement of NexoBrid va
Read more →MDWDMediWound to Report Fourth Quarter & Fiscal 2019 Financial Results and Host a Conference Call and Webcast on February 25, 2020
YAVNE, Israel, Feb. 18, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial resul
Read more →MDWDMediWound Expands its Distribution Agreement with GENFA MEDICA SA to Market NexoBrid in Ukraine and the Baltic States
YAVNE, Israel, Jan. 13, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the expansion of its agreement with GENFA MEDICA
Read more →MDWDMediWound Continues NexoBrid’s Global Expansion Through a New Distribution Agreement in Australia, New Zealand and Singapore with Balance Medical
YAVNE, Israel, Jan. 02, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the signing of a distribution agreement granting
Read more →MDWDMediWound Initiates U.S. Phase 2 Adaptive Design Study of EscharEx for Treatment of Venous Leg Ulcers
YAVNE, Israel, Dec. 03, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (the “Company”) (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the initiation of patient treatme
Read more →MDWDMediWound Reports Third Quarter 2019 Financial Results
Total revenues of $5.1 million, driven primarily by revenues from development services Initiated U.S. NexoBrid expanded access treatment (NEXT) protocol, with plans on track for NexoBrid® BLA filing in the second quarter of 2020 Expected to initiate patient treatment in EscharE
Read more →MDWDMediWound to Report Third Quarter 2019 Financial Results and Host a Conference Call and Webcast on November 14
YAVNE, Israel, Nov. 06, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial resul
Read more →MDWDMediWound Reports Second Quarter 2019 Financial Results
Total revenues of $20.7 million, driven primarily by the upfront payment from Vericel for NexoBrid® license agreement BARDA committed additional $21 million to fund NexoBrid® expanded access treatment protocol Confirmed BLA submission plans in a pre-BLA meeting with FDA Compan
Read more →MDWDMediWound to Report Second Quarter 2019 Financial Results and Host a Conference Call and Webcast on August 13
YAVNE, Israel, Aug. 06, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial resul
Read more →MDWDMediWound Launches EscharEx U.S. Clinical Development Program
Company’s primary focus turns to EscharEx following its successful collaboration for NexoBrid Company to initiate an adaptive comprehensive adequately controlled study in 4Q 2019 Company to host Analyst Day today, July 22, in New York, NY YAVNE, Israel, July 22, 2019 (GLOBE NE
Read more →MDWDMediWound to Host Analyst Day on its Innovative Product EscharEx for Debridement of Chronic Wounds
YAVNE, Israel, July 16, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, will host an analyst day on its innovative product for chronic wo
Read more →MDWDMediWound Appoints Mr. Boaz Gur-Lavie as Chief Financial Officer
YAVNE, Israel, June 11, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the appointment of Mr. Boaz Gur-Lavie as Chief Fi
Read more →MDWDMediWound Reports First Quarter 2019 Financial Results
Met Primary and All Secondary Endpoints in Pivotal Phase 3 DETECT Study; NexoBrid BLA Filing Planned for Fourth Quarter of 2019 Signed Exclusive License Agreement with Vericel for Commercial Rights to NexoBrid® in North America Conference call begins today at 8:30 a.m. Eastern
Read more →MDWDMediWound to Host First Quarter Financial Results Conference Call on May 21at 8:30 a.m. Eastern Time
YAVNE, Israel, May 14, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial result
Read more →MDWDMediWound Enters into Exclusive License Agreement with Vericel for Commercial Rights to NexoBrid in North America
$17.5 million upfront, sales royalties and up to $132.5 million in potential milestones Leverages Vericel’s Commercial Capabilities and Presence in U.S. Burn Care Market Biologics License Application (BLA) Filing Planned for Fourth Quarter of 2019 Company to Host a Conference
Read more →MDWDMediWound Files Annual Report on Form 20-F for the Year Ended December 31, 2018
YAVNE, Israel, March 26, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that it has filed its annual report on Form 20-F
Read more →MDWDMediWound Reports Fourth Quarter and Fiscal Year 2018 Financial Results
Met Primary and All Secondary Endpoints in its Pivotal Phase 3 Study (DETECT) in NexoBrid® for Eschar Removal of Severe Thermal Burns Awarded Additional BARDA Contract Valued up to $43 Million for the Development of NexoBrid for Sulfur Mustard Injuries Conference call begins to
Read more →MDWDMediWound to Host Fourth Quarter & Fiscal 2018 Financial Results Conference Call on March 25 at 8:30 a.m. Eastern Time
YAVNE, Israel, March 18, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial resu
Read more →MDWDMediWound Announces Executive Leadership Changes
Chief Executive Officer Gal Cohen stepping down Available for transition and ongoing strategic process support Chief Financial & Operations Officer Sharon Malka will be appointed CEO Chairmen of the Board Stephen T. Wills will serve as Active Chairman YAVNE, Israel, March 12,
Read more →MDWDMediWound Announces Positive Top-Line Results from Its Pivotal Phase 3 Study (DETECT) in NexoBrid for Eschar Removal of Severe Thermal Burns
Met Primary and All Secondary Endpoints with Statistically Significant Results Compared with Control Group Conference call with MediWound management and U.S. key opinion leader begins today, January 22, 2019 at 10:00 a.m. Eastern time YAVNE, Israel, Jan. 22, 2019 (GLOBE NEWSWIR
Read more →MDWDMediWound Reports Third Quarter 2018 Financial Results
Awarded additional BARDA contract valued up to $43 Million for the development of NexoBrid® for sulfur mustard injuries Conference call begins today at 8:30 a.m. Eastern Time YAVNE, Israel, Nov. 13, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biop
Read more →MDWDMediWound to Host Third Quarter 2018 Financial Results Conference Call on November 13 at 8:30 a.m. Eastern Time
YAVNE, Israel, Nov. 07, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial resul
Read more →MDWDMediWound Awarded Additional BARDA Contract Valued Up to $43 Million for Development of NexoBrid for Sulfur Mustard Injuries
YAVNE, Israel, Sept. 24, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the U.S. Biomedical Advanced Research and D
Read more →MDWDMediWound to Present at 13th Annual Wells Fargo Securities Healthcare Conference
YAVNE, Israel, Sept. 04, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will present a corporate overvi
Read more →MDWDMediWound Reports Second Quarter 2018 Financial Results
Completion of enrollment of Phase 3 DETECT Study of NexoBrid® Strategic discussions advancing with multiple parties Conference call begins today at 8:30 a.m. Eastern Time YAVNE, Israel, Aug. 07, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biophar
Read more →MDWDMediWound to Host Second Quarter 2018 Financial Results Conference Call on August 7 at 8:30 a.m. Eastern Time
YAVNE, Israel, July 31, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial result
Read more →MDWDMediWound Expands Its NexoBrid Phase 3 Children Innovation Debridement Study (CIDS) to the U.S.
Study fully funded by BARDA YAVNE, Israel, June 19, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the expansion of its
Read more →MDWDMediWound Completes Enrollment in NexoBrid U.S. Phase 3 DETECT Study
Top-line acute data currently expected around year end 2018 YAVNE, Israel, June 11, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today
Read more →MDWDMediWound Reports First Quarter 2018 Financial Results
Anticipates completion of enrollment of Phase 3 DETECT Study of NexoBrid® around mid-2018 Conference call begins today at 8:30 a.m. Eastern Time YAVNE, Israel, May 10, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing i
Read more →MDWDMediWound to Host First Quarter 2018 Financial Results Conference Call on May 10 at 8:30 a.m. Eastern Time
YAVNE, Israel, May 04, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release financial results for
Read more →MDWDMediWound’s NexoBrid to be Highlighted in Presentations at the American Burn Association 50th Annual Meeting Being Held on April 10-13, 2018 in Chicago
Presentations highlight European consensus around the efficacy and benefits of NexoBrid use in severe burns YAVNE, Israel, April 09, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet
Read more →MDWDMediWound Reports Fourth Quarter and Fiscal Year 2017 Financial Results
NexoBrid® sales grow 60% in 2017 vs. 2016 Raised gross proceeds of $25.2 million through an equity offering to fund EscharEx® clinical plan Awarded additional $32 million from BARDA bringing NexoBrid® to be self-funded program Announces discussions regarding potential strate
Read more →MDWDMediWound to Host Fourth Quarter and Fiscal Year 2017 Financial Results Conference Call on March 19 at 8:30 a.m. Eastern Time
YAVNE, Israel, March 13, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release financial results f
Read more →MDWDMediWound to Present at Two Investor Conferences
YAVNE, Israel, March 08, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will present a corporate overvie
Read more →MDWDMediWound Reports Third Quarter 2017 Financial Results
NexoBrid® sales grow 74% year-to-date Raised gross proceeds of $25.2 million through public equity offering Awarded additional $32 million from BARDA to support NexoBrid R&D programs Conference call begins today at 8:30 a.m. Eastern Standard Time YAVNE, Israel, Nov. 16, 2017
Read more →MDWDMediWound to Host Third Quarter 2017 Financial Results Conference Call on November 16, 2017 at 8:30 a.m. Eastern Time
YAVNE, Israel, Nov. 10, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release financial res
Read more →MDWDMediWound Announces Exercise of Underwriters’ Option to Purchase Additional Shares
YAVNE, Israel, Oct. 27, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, today announced that the underwriters of its previously ann
Read more →MDWDMediWound Appoints Mr. Stephen T. Wills as Chairman to its Board of Directors
YAVNE, Israel, Oct. 25, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, today announced the appointment of Mr. Stephen T. Wills as
Read more →MDWDMediWound Further Expands NexoBrid’s Global Outreach through New Distribution Agreement in Taiwan with Holy Stone Healthcare
YAVNE, Israel, Oct. 16, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company specializing in the development of innovative therapies to address unmet needs in severe burn and wound management, today announced an agreement with Holy S
Read more →MDWDMediWound Ltd. Announces Pricing of $22 Million Public Offering of Ordinary Shares
YAVNE, Israel, Sept. 19, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD) today announced the pricing of an underwritten public offering of 4,400,000 of its ordinary shares at a price to the public of $5.00 per share. All of the ordinary shares are being offered by MediWound
Read more →MDWDMediWound Ltd. Announces Public Offering of Ordinary Shares
YAVNE, Israel, Sept. 18, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, today announced that it has commenced an underwritten publ
Read more →MDWDMediWound’s NexoBrid Wins Best Poster Presentation Award at the 17th European Burns Association Congress
Award-winning Poster Underscores European Consensus on Benefits of NexoBrid YAVNE, Israel, Sept. 11, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and
Read more →MDWDMediWound’s NexoBrid Highlighted in 43 Presentations at the 17th European Burns Association Congress
YAVNE, Israel, Sept. 06, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, today announced that 43 scientific presentations highlight
Read more →MDWDMediWound Successfully Completes Second Cohort of EscharEx Phase 2 Study
YAVNE, Israel, Sept. 01, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, reports positive top-line results from the second cohort of the C
Read more →MDWDMediWound Reports Second Quarter 2017 Financial Results
NexoBrid® sales double in first half of 2017 BARDA upsizes committed funding by additional $32 million, bringing total contract value to up to $132 million of non-dilutive financing Conference call begins today at 8:30 a.m. Eastern time YAVNE, Israel, Aug. 03, 2017 (GLOBE NEWS
Read more →MDWDMediWound to Host Second Quarter 2017 Financial Results Conference Call on August 3, 2017 at 8:30 a.m. Eastern Time
YAVNE, Israel, July 28, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release financial res
Read more →MDWDMediWound to Present at the Jefferies Global Healthcare Conference
YAVNE, Israel, June 05, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that management will participate at the Jefferies 2017 G
Read more →MDWDMediWound Announces Changes to its Board of Directors
YAVNE, Israel, May 18, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that the Board of Directors has appointed Vickie R. Drive
Read more →MDWDMediWound Reports First Quarter 2017 Financial Results
YAVNE, Israel, May 08, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, reports financial results for the three months ended March 31, 2017
Read more →MDWDMediWound Announces Successful GMP Manufacturing Audit by the Israeli Ministry of Health
YAVNE, Israel, May 03, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces the successful completion of a Good Manufacturing Practic
Read more →MDWDMediWound to Host First Quarter 2017 Financial Results Conference Call on May 8, 2017 at 8:30 a.m. Eastern Time
YAVNE, Israel, May 01, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announces that the Company will release financial results for
Read more →MDWDMediWound’s NexoBrid and EscharEx to be Highlighted in Multiple Presentations at the Symposium on Advanced Wound Care Spring
YAVNE, Israel, March 30, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that seven presentations highlighting the positive clin
Read more →MDWDMediWound Announces Conference Call and Webcast of “Meet the Experts” Panel Discussion Chaired by SunTrust Robinson Humphrey at the 49th American Burn Association Annual Meeting
YAVNE, Israel, March 17, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, announces that a “Meet the Expert” panel chaired by SunTru
Read more →MDWDMediWound’s NexoBrid and EscharEx to be Highlighted in Presentations at the American Burn Association 49th Annual Meeting
YAVNE, Israel, March 14, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that 6 presentations highlighting the positive results
Read more →MDWDMediWound to Present at the Oppenheimer 27th Annual Healthcare Conference
YAVNE, Israel, March 13, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that Company management will participate at the Oppenhe
Read more →MDWDMediWound Reports 2016 Fourth Quarter and Full Year Financial Results
YAVNE, Israel, Feb. 21, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, reports financial results for the three and 12 months ended Decemb
Read more →MDWDMediWound to Host 2016 Fourth Quarter and Full Year Financial Results Conference Call on February 21, 2017 at 8:30 a.m. Eastern Time
YAVNE, Israel, Feb. 14, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announces that the Company will release financial results fo
Read more →MDWDMediWound Initiates Second Stage of European Pediatric Phase 3 Study of NexoBrid Expanding Treatment of Severe Burns to Children Age One to Four
YAVNE, Israel, Feb. 06, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that the European Medicines Agency (EMA) has endorsed th
Read more →MDWDMediWound Reports Final Positive Results of Phase 2 Clinical Trial of EscharEx for the Debridement of Chronic and Hard-to-Heal Wounds
YAVNE, Israel, Jan. 31, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces final positive results from the Company’s second Phase 2
Read more →MDWDMediWound Granted U.S. Patent for MWPC003 for the Treatment of Connective Tissue Diseases
YAVNE, Israel, Dec. 20, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that the United States Patent and Trademark Office (USPT
Read more →MDWDMediWound Reports Third Quarter 2016 Financial Results
YAVNE, Israel, Nov. 14, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, reports financial results for the three and nine months ended Sept
Read more →MDWDMediWound to Host Third Quarter 2016 Financial Results Conference Call on November 14, 2016 at 8:30 a.m. Eastern Time
YAVNE, Israel, Nov. 04, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announces that the Company will release financial results fo
Read more →MDWDMediWound to Present at the Credit Suisse 25th Annual Healthcare Conference
YAVNE, Israel, Nov. 01, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that Company management will participate at the Credit S
Read more →MDWDMediWound to Present at 11th Annual Wells Fargo Healthcare Conference
YAVNE, Israel, Aug. 26, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that Company management will participate at the 11th Ann
Read more →MDWDMediWound’s NexoBrid and EscharEx to be Featured at International Society for Burn Injuries 2016
YAVNE, Israel, Aug. 24, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company’s NexoBrid® and EscharEx® will be
Read more →MDWDMediWound Reports Second Quarter 2016 Financial Results
YAVNE, Israel, July 28, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, reports financial results for the three and six months ended June
Read more →MDWDMediWound to Host Second Quarter 2016 Financial Results Conference Call on July 28, 2016 at 8:30 a.m. Eastern Time
YAVNE, Israel, July 21, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announces that the Company will release financial results f
Read more →MDWDMediWound’s NexoBrid Receives Reimbursement in Italy
YAVNE, Israel, June 07, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that the Board of the Italian Drug Agency (AIFA) has app
Read more →MDWDMediWound to Present at Jefferies 2016 Healthcare Conference
YAVNE, Israel, June 01, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that Company management will participate at Jefferies 20
Read more →MDWDMediWound’s NexoBrid Highlighted in “Best Oral Presentation” at the British Burn Association 49th Annual Conference and Scientific Meeting
YAVNE, Israel, May 19, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that an abstract highlighting the merits of NexoBrid® in
Read more →MDWDMediWound’s NexoBrid to be Highlighted in Presentations at the American Burn Association 48th Annual Meeting
YAVNE, Israel, May 02, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that 11 presentations highlighting the positive results a
Read more →MDWDMediWound’s NexoBrid to be Available in Japan through Kaken Pharmaceuticals Co., Ltd.
YAVNE, Israel, April 26, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces the signing of an agreement granting Kaken Pharmaceutic
Read more →MDWDMediWound Reports First Quarter 2016 Financial Results
YAVNE, Israel, April 21, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, reports financial results for the three months ended March 31, 20
Read more →MDWDMediWound to Host First Quarter 2016 Financial Results Conference Call on April 21, 2016 at 8:30 a.m. Eastern Time
YAVNE, Israel, April 14, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announces that the Company will release financial results
Read more →MDWDMediWound to Present at Needham & Company’s 15th Annual Healthcare Conference
YAVNE, Israel, April 06, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that Company management will participate at Needham & C
Read more →MDWDMediWound to Present at the 36th Annual Cowen Health Care Conference
YAVNE, Israel, March 07, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that Company management will participate at the 36th An
Read more →MDWDMediWound Expands NexoBrid to India, Bangladesh and Sri Lanka Through Distribution Agreement With Learning Organized LLC
YAVNE, Israel, Feb. 29, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces the signing of an agreement granting Learning Organized
Read more →MDWDMediWound’s EscharEx Meets Primary Endpoint in Second Phase 2 Clinical Trial for the Debridement of Chronic and Hard-to-Heal Wounds
Data demonstrate strong results in diabetic foot ulcers and venous leg ulcers Conference call with MediWound management and key opinion leader begins February 3, 2016 at 8:30 a.m. Eastern time YAVNE, Israel, Feb. 02, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a full
Read more →MDWDMediWound Reports 2015 Fourth Quarter and Full Year Financial Results
YAVNE, Israel, Jan. 25, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, reports financial results for the three and 12 months ended Decemb
Read more →MDWDMediWound Expands Latin American Distribution of NexoBrid Through Agreement With Avalon Pharmaceutical S.A
YAVNE, Israel, Jan. 21, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces the signing of an agreement granting Avalon Pharmaceutic
Read more →MDWDMediWound to Host Fourth Quarter and Year End 2015 Financial Results Conference Call on January 25, 2016 at 8:30 a.m. Eastern Time
YAVNE, Israel, Jan. 19, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release financial results f
Read more →MDWDMediWound’s NexoBrid Highlighted in Presentations at the 4th International Conference on Healthcare System Preparedness and Response to Emergencies and Disasters
YAVNE, Israel, Jan. 11, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that two presentations highlighting NexoBrid’s potential
Read more →MDWDMediWound Appoints Aharon Yaari as Chairman of Its Board of Directors
YAVNE, Israel, Dec. 23, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, announces today the appointment of Mr. Aharon Yaari as the
Read more →MDWDMediWound to Present at the Oppenheimer 26th Annual Healthcare Conference
YAVNE, Israel, Dec. 1, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, announces that Company management will participate at the Op
Read more →MDWDMediWound Appoints Aharon Yaari to Its Board of Directors
YAVNE, Israel, Dec. 1, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, announces today the appointment of Aharon Yaari to the Compa
Read more →MDWDMediWound to Present at the Canaccord Genuity 2015 Medical Technology & Diagnostics Forum
YAVNE, Israel, Nov. 12, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, announces that Company management will participate at the C
Read more →MDWDMediWound to Present at the Credit Suisse 24th Annual Healthcare Conference
YAVNE, Israel, Nov. 6, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, announces that Company management will participate at the Cr
Read more →MDWDMediWound Appoints Dr. Roland Frosing as European Medical Director
YAVNE, Israel, Nov. 5, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, announces the appointment of Roland Fr sing M.D., Ph.D. as M
Read more →MDWDMediWound Provides Humanitarian Aid for a Mass Casualty Event in Romania
YAVNE, Israel, Nov. 2, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, announced today that it has provided its flagship product, N
Read more →MDWDMediWound Reports Third Quarter 2015 Financial Results
YAVNE, Israel, Oct. 27, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today reported financial results for the three and nine months en
Read more →MDWDMediWound to Host Third Quarter 2015 Financial Results Conference Call on October 28 at 8:30 a.m.
YAVNE, Israel, Oct. 16, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release financial results f
Read more →MDWDMediWound Awarded BARDA Contract Valued Up to $112 Million for Development and Procurement of NexoBrid for the U.S.
YAVNE, Israel, Sept. 30, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, announces that the U.S. Biomedical Advanced Research and D
Read more →MDWDMediWound Reports Highlights From the European Burns Association Congress
YAVNE, Israel, Sept. 29, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, reports highlights from the 26 scientific presentations,
Read more →MDWDMediWound Announces Conference Call and Webcast of "Meet the Experts" Panel Discussion Chaired by BMO Capital Markets at the 16th European Burns Association Congress
YAVNE, Israel, Sept. 14, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, announces that a "Meet the Expert" panel chaired by BMO Ca
Read more →MDWDMediWound's NexoBrid(R) Highlighted at the 16th European Burns Association Congress
YAVNE, Israel, Sept. 10, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, announces that an industrial workshop, satellite symposium
Read more →MDWDMediWound Completes Enrollment in Second Phase 2 Clinical Trial of EscharEx(R) to Treat Chronic and Other Hard-to-Heal Wounds
YAVNE, Israel, Sept. 1, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that it has completed the enrollment of its second Phas
Read more →MDWDMediWound Reports Second Quarter 2015 Financial Results
YAVNE, Israel, Aug. 3, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today reported financial results for the three and six months ended
Read more →MDWDMediWound to Host Second Quarter 2015 Financial Results Conference Call on August 4 at 8:30 a.m. ET
YAVNE, Israel, July 28, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release financial results f
Read more →MDWDMediWound Approved for First Grant to Support EscharEx(TM) Development Program
YAVNE, Israel, June 11, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company developing, manufacturing and commercializing innovative therapies to address unmet needs in severe burn and wound management, announces that the Company h
Read more →MDWDMediWound to Present at Jefferies 2015 Global Healthcare Conference
YAVNE, Israel, June 1, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company developing, manufacturing and commercializing innovative therapies to address unmet needs in severe burn and wound management, announces that Company manage
Read more →MDWDMediWound Reports First Quarter 2015 Financial Results
YAVNE, Israel, May 4, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today reported financial results for the three months ended March 31
Read more →MDWDMediWound to Host First Quarter 2015 Financial Results Conference Call on May 4, 2015 at 8:30 a.m.
YAVNE, Israel, April 23, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release financial results
Read more →MDWDMediWound's NexoBrid(R) Highlighted in Presentations at the 2015 American Burn Association 47th Annual Meeting
YAVNE, Israel, April 21, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that three presentations highlighting the positive resu
Read more →MDWDMediWound Initiates U.S. Phase 3 Trial With NexoBrid(R) to Treat Severe Burns
YAVNE, Israel, April 20, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces initiation of the DETECT (DEbride and ProTECT) U.S. Phase 3 clinical stu
Read more →MDWDMediWound's NexoBrid Highlighted in a Presentation at the International Conference on Minimally Invasive Medicine
YAVNE, Israel, March 23, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that Prof. Lior Rosenberg, M.D., the Company's Chief Me
Read more →MDWDMediWound to Host Fourth Quarter and Year End 2014 Financial Results Conference Call on February 12, 2015 at 8:30 a.m. Eastern Time
YAVNE, Israel, Feb. 6, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release financial results fo
Read more →MDWDMediWound to Ring the NASDAQ Stock Market Closing Bell on February 5, 2015 in Recognition of Burn Awareness Week
YAVNE, Israel, Feb. 4, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Gal Cohen, MediWound's Chief Executive Office
Read more →MDWDMediWound Ltd. (Nasdaq: MDWD) to Ring The Nasdaq Stock Market Closing Bell
ADVISORY, Feb. 04, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, will visit the Nasdaq MarketSite in Times Square in recognition of Bur
Read more →MDWDMediWound's NexoBrid to be Featured at International Society for Burn Injuries 2014
YAVNE, Israel, Oct. 7, 2014 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company's NexoBrid will be featured in mu
Read more →MDWDMediWound Reports Second Quarter 2014 Financial Results
YAVNE, Israel, July 31, 2014 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today reported financial results for the three and six months ende
Read more →MDWDMediWound to Host Second Quarter 2014 Financial Results Conference Call on July 31, 2014 at 8:30 a.m.
YAVNE, Israel, July 22, 2014 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release financial results f
Read more →MDWDMediWound Announces NexoBrid Marketing Approval From Israeli Ministry of Health
YAVNE, Israel, July 16, 2014 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announced today that the Company has received authorization from
Read more →MDWDMediWound to Present at Jefferies 2014 Global Healthcare Conference
YAVNE, Israel, June 2, 2014 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company developing, manufacturing and commercializing innovative therapies to address unmet needs in severe burn and wound management, announces that Company manage
Read more →MDWDMediWound Expands Distribution of NexoBrid to South Korea Through Agreement With BexPharm Korea
YAVNE, Israel, May 30, 2014 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announced today the signing of an agreement granting BexPharm Korea
Read more →MDWDMediWound Initiates Second Phase 2 Clinical Trial of EscharEx(TM) to Treat Chronic and Other Hard-to-Heal Wounds
YAVNE, Israel, May 21, 2014 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces initiation of its second Phase 2 clinical trial of Escha
Read more →MDWDMediWound Completes Recruitment of Commercial Management Team in Europe
YAVNE, Israel, May 12, 2014 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces completion of recruitment of its commercial management t
Read more →MDWDMediWound Expands Distribution of NexoBrid to Russia Through Agreement With Genfa Medica
YAVNE, Israel, May 8, 2014 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announced today the signing of an agreement granting Genfa Medica,
Read more →MDWDMediWound Announces Extraordinary General Meeting of Shareholders
YAVNE, Israel, May 5, 2014 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD) (the "Company"), today announced that it will hold an Extraordinary General Meeting of Shareholders on Thursday, June 12, 2014. The record date for shareholders entitled to vote at the meeting is Monday,
Read more →MDWDMediWound Reports First Quarter 2014 Financial Results
YAVNE, Israel, May 2, 2014 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, reports today its financial results for the three months ended March
Read more →MDWDMediWound Announces Closing of Initial Public Offering
YAVNE, Israel, March 25, 2014 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company developing, manufacturing and commercializing innovative therapies to address unmet needs in severe burn and wound management, today announced the closing
Read more →MDWDMediWound Prices Initial Public Offering
YAVNE, Israel, March 20, 2014 (GLOBE NEWSWIRE) -- MediWound Ltd., a fully-integrated, biopharmaceutical company developing, manufacturing and commercializing innovative therapies to address unmet needs in severe burn and wound management, announced today the pricing of its initia
Read more →MDWDMediWound -- Positive Recommendation for Marketing Authorization From the European Medicines Agency for Its Innovative Drug -- NexoBrid(TM)
TEL AVIV, Israel, Sept. 24, 2012 (GLOBE NEWSWIRE) -- Clal Biotechnology, (TASE:CBI), a leading investment company in the field of life sciences, is pleased to announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recomm
Read more →Competitive Position
How MDWD ranks across every disease it competes inCompetitive Position is a premium feature
See how MDWD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial